Table 5.
Characteristics of P-CR who participated to CR programs between 2009 and 2013 (Subgroup1) and between 2014 and 2016 (Subgroup2).
| Cognitive Remediation | 2009–2013 (n = 37) | 2014–2016 (n = 29) | p value* |
|---|---|---|---|
| n or mean (% or SD) | n or mean (% or SD) | ||
| Socio-Demographics | |||
| Male Sex | 20 (54.1) | 21 (72.4) | 0.048 |
| Age | 41,3 (11.5) | 34,0 (10.7) | 0.041 |
| Years of study | 13,2 (2.9) | 13,7 (2.7) | 0.539 |
| Diagnostics | |||
| Schizophrenia | 34 (91.9) | 19 (65.5) | |
| Bipolar | 1 (2.7) | 2 (6.9) | |
| Neurodevelopmental Disorder | 2 (5.4) | 8 (27.6) | 0.026 |
| Programs | |||
| CR Combination | 1 (2.7) | 6 (20.7) | 0.019 |
| CR in Group | 1 (2.7) | 12 (41.4) | <0.001 |
| CR Social cognition | 1 (2.7) | 5 (17.2) | 0.041 |
| Psychosocial Therapies | 11 (29.7) | 14 (48.3) | 0.123 |
| Any Treatment at T2 | 36 (97.3) | 27 (93.1) | 0.417 |
| Antipsychotics | 36 (97.3) | 27 (93.1) | 0.417 |
| Clozapin | 18 (48.7) | 7 (24.2) | 0.042 |
| Depot antipsychotics | 3 (8.1) | 6 (20.7) | 0.139 |
| Depot 1 injection/15 days | 0 (0.0) | 0 (0.0) | 0.325 |
| Equivalent chlorpromazine | 259,4 (199.3) | 184,5 (190.1) | 0.127 |
| Antidepressants | 17 (45.9) | 9 (31.0) | 0.219 |
| Mood stabilizers | 7 (18.9) | 6 (20.7) | 0.858 |
| Benzodiazepins | 5 (13.5) | 5 (17.2) | 0.675 |
| Anxiolytics or hypnotics | 2 (5.4) | 1 (3.4) | 0.705 |
| Methylphenidate | 2 (5.4) | 1 (3.4) | 0.705 |
| Type of outcomes since T2 (in 2017–2018) | |||
| Professional activity | 26 (70.3) | 13 (44.8) | 0.037 |
| Open jobs | 18 (48.7) | 6 (20.7) | 0.019 |
| Users performing studies | 7 (18.9) | 13 (44.8) | 0.023 |
| Users performing open studies | 6 (16.2) | 11 (39.3) | 0.036 |
| Independent Housing | 23 (62.1) | 18 (62.1) | 0.994 |
| Leisure (Reading) | 16 (43.2) | 12 (41.4) | 0.879 |
| Physical activity | 21 (56.8) | 13 (44.8) | 0.336 |
| No relapse | 21 (56.8) | 23 (79.1) | 0.054 |
*Pearson Chi-square Test or independent sample t test.